SGLT2 抑制剂与听力损失之间的关系:全国性基于人口的回顾性队列研究
Chia-Huei Chu1,2, Yi-Chao Hsu2,3, Chang-Yin Lee4,5,6
1Department of Otolaryngology - Head Neck Surgery, MacKay Memorial Hospital, Taipei, Taiwan.
Diabetology & metabolic syndrome
|December 30, 2025
概括
-葡萄糖共传输体-2 抑制剂 (SGLT2i) 可能降低 2 型糖尿病 (T2DM) 患者感觉神经听力损失 (SNHL) 的风险. 持续使用SGLT2i显示出显著的剂量反应关联与较低的SNHL发病率.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 感觉神经听力损失 (SNHL) 是2型糖尿病 (T2DM) 的一个未被认可的并发症.
- -葡萄糖共传递剂-2 抑制剂 (SGLT2i) 提供了超出血糖控制的好处,但它们的听觉效果尚不清楚.
研究的目的:
- 调查SGLT2i使用与T2DM患者SNHL风险之间的关联.
主要方法:
- 一项全国性的队列研究利用了台湾国家健康保险研究数据库 (2000-2021).
- 倾向性得分匹配 (1:1) 与接受SGLT2i≥90天的T2DM患者与非使用者进行了比较.
- 主要结局是SNHL发病率,通过听力测试得到确认.
主要成果:
- 分析了381,592名T2DM患者.
- SGLT2i使用者的SNHL风险显著降低 (aHR=0.84;95%CI:0.75-0.94).
- 长期使用SGLT2i (≥366天) 显示出强烈的剂量反应关系与降低SNHL风险 (aHR=0.32;95%CI:0.27-0.39).
结论:
- 在T2DM患者中,SGLT2i的使用与SNHL风险降低有关.
- 持续的SGLT2i治疗显示出明显的保护作用,防止听觉并发症.
- 这表明在综合糖尿病管理中考虑SGLT2i用于听力健康.
相关概念视频
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
216
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
216
01:27Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K